Skin Diseases, Genetic clinical trials
The registry lists 25 studies for Skin Diseases, Genetic across more than 10 countries. 7 are recruiting or about to start. 1 of them are mainly about Skin Diseases, Genetic (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-12. Counting its 27 narrower conditions too, such as Dermatitis, Atopic: 2,703 studies, 566 open.
Get an email when these change. Save the Skin Diseases, Genetic studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Who runs them
Pfizer (4) · National Cancer Institute (NCI) (2) · Merz North America, Inc. (2) · Centre Hospitalier Universitaire de Nice (2) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) (1) · Queen Fabiola Children's University Hospital (1) · Dermata Therapeutics (1)
What is being tested here
Drugs under test in Skin Diseases, Genetic studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
| Drug | Open | Phase 3 | All |
|---|---|---|---|
| Tilrekimig | 2 | 2 | 2 |
| Doxycycline | 1 | 0 | 1 |
| Abrocitinib | 0 | 2 | 2 |
| Deucravacitinib | 0 | 0 | 1 |
| Benralizumab | 0 | 0 | 1 |
| Desloratadine | 0 | 1 | 1 |
| Lebrikizumab | 0 | 1 | 1 |
Drug classes tested here JAK inhibitors 3 · Tyrosine kinase inhibitors (TKIs) 3
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
All 2, phase 3 first
- Mar 2027Herbal Ointment in Treating Atopic Dermatitis Topically · Phase 3 · En Chu Kong Hospital
- Jan 2027Effects of Treatments on Atopic Dermatitis · National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Who these studies take
Of the 7 Skin Diseases, Genetic studies recruiting now, 4 (57%) set no upper age limit and 2 (29%) stop at 75 or younger. 6 (86%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 2 (29%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 4 (57%) | 4 (57%) |
| 18 | 7 (100%) | 7 (100%) |
| 30 | 7 (100%) | 7 (100%) |
| 40 | 7 (100%) | 7 (100%) |
| 50 | 7 (100%) | 7 (100%) |
| 65 | 6 (86%) | 6 (86%) |
| 75 | 5 (71%) | 5 (71%) |
| 85 | 5 (71%) | 5 (71%) |
Across all 25 studies, recruiting or not: 32% stop at 75 or younger and 32% at 65; 76% take children; 4% are for women only and 0% for men only; 24% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
Studies
Recruiting first, then most recently updated. Showing 25 of 25. search them.
- Effects of Treatments on Atopic DermatitisRecruitingNCT01631617Phase 21 country
- A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to-Severe EczemaRecruitingNCT07765888Phase 33 countries
- A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to Severe EczemaRecruitingNCT07783425Phase 34 countries
- GMEB-SASS: A Gene-Modified Skin Substitute for RDEB TreatmentRecruitingNCT07193134Phase 1/21 country
- Herbal Ointment in Treating Atopic Dermatitis TopicallyRecruitingNCT06850311Phase 2/31 country
- A 20-Week Study Assessing the Efficacy of Apremilast in Patients with EB Simplex GeneralizedRecruitingNCT06509984Phase 21 country
- Computational Drug Repurposing for All EBS CasesRecruitingNCT032694741 country
- Examination of Clinical and Laboratory Abnormalities in Patients With Defective DNA Repair: Xeroderma Pigmentosum, Cockayne Syndrome, or TrichothiodystrophyCompletedNCT000018131 country
- A 44-week Monocentric Open Study Assessing the Efficacy and Safety of Deucravacitinib in Adults With Inflammatory GenodermatosesCompletedNCT06136403Phase 21 country
- Artificial Intelligence Patient App for RDEB SCCsActive, not recruitingNCT058439941 country
- Effect of Benralizumab in Atopic DermatitisCompletedNCT03563066Phase 21 country
- Efficacy and Safety Study of Desloratadine (MK-4117) in Japanese Participants With Eczema/Dermatitis and Dermal Pruritus (MK-4117-202)CompletedNCT01916980Phase 3
- A Study of Lebrikizumab (LY3650150) in Combination With Topical Corticosteroids in Japanese Participants With Moderate-to-Severe Atopic DermatitisCompletedNCT04760314Phase 31 country
- Allogeneic ABCB5-positive Stem Cells for Treatment of Epidermolysis BullosaCompletedNCT03529877Phase 1/25 countries
- Epidemiological Survey and Genetic Analysis of AD Patients in Hong KongStatus unknownNCT041548391 country
- Study to Investigate Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years and Over With Moderate to Severe Atopic Dermatitis With the Option of Rescue Treatment in Flaring SubjectsCompletedNCT03627767Phase 321 countries
- Study Evaluating Efficacy and Safety of PF-04965842 and Dupilumab in Adult Subjects With Moderate to Severe Atopic Dermatitis on Background Topical TherapyCompletedNCT03720470Phase 318 countries
- A Study Evaluating the Safety and Efficacy of Topical BPR277 for the Treatment of Atopic Dermatitis and Netherton SyndromeCompletedNCT01428297Phase 12 countries
- Method of Genetic Analysis in GenodermatosesStatus unknownNCT03873285Not applicable1 country
- DMT210 Topical Gel in the Treatment of Atopic DermatitisCompletedNCT02949960Phase 21 country
- A Study Comparing the Quality of Life of Patients in the Treatment of Eczema by Pediatric Generalists and SpecialistsCompletedNCT029168881 country
- Atopic Dermatitis Research Network (ADRN) Influenza Vaccine StudyCompletedNCT01737710Not applicable1 country
- Efficacy and Safety Study of MSRD-100 in Subjects With Atopic Dermatitis >=3 Months of Age and OlderWithdrawnNCT02677610Phase 3
- Efficacy and Safety Study of MSRD-100 in Subjects With Atopic Dermatitis >=3 Months of Age and OlderWithdrawnNCT02677636Phase 3
- Study of Scaling Disorders and Other Inherited Skin DiseasesCompletedNCT000012921 country